Literature DB >> 34189045

Native valve endocarditis and pacemaker infection with Mycobacterium fortuitum.

Moamen Al Zoubi1,2, Joyce Cheng2, Venkate S Dontaraju2, Colin E Evans3, Addie B Spier1,2.   

Abstract

Endocarditis and cardiac device infection due to Mycobacterium fortuitum is a rare entity in the hospital settings. We report a case of pacemaker infection and native valve endocarditis due to Mycobacterium fortuitum, which was associated with tricuspid valve vegetation. two days after admission with fever, chills, body aches and swelling around her pacemaker, the patient's pacing system was surgically removed. The patient was then discharged at day 16 after surgery and treated with a multidrug regimen of azithromycin, levofloxacin, imipenem/cilastatin, and amikacin for six weeks followed by trimethoprim/sulfamethoxazole plus doxycycline for a further three months.

Entities:  

Keywords:  Cardiac pacemaker; Defibrillator; Mycobacterium fortuitum; Nontuberculous mycobacteria

Year:  2021        PMID: 34189045      PMCID: PMC8220318          DOI: 10.1016/j.idcr.2021.e01200

Source DB:  PubMed          Journal:  IDCases        ISSN: 2214-2509


Introduction

Mycobacterium fortuitum, a member of rapidly growing nontuberculous mycobacteria, is a well-known cause of skin and soft tissue infections and postsurgical wound infection. Here, we describe a case of native tricuspid valve endocarditis and pacemaker infection secondary to M. fortuitum. We also review the published literature of cardiac device–associated infections and native valve endocarditis caused by M. fortuitum.

Case report

A 26-year-old female presented to our hospital for evaluation of fever, chills, body aches and swelling around her pacemaker generator of 5 days duration. Four weeks prior, she had implantable cardioverter-defibrillator (ICD) placement for prevention of sudden cardiac death in the setting of ventricular arrhythmias. Vital signs revealed a temperature 38.9 F, pulse 90bpm, and blood pressure 117/76 mmHg. Her physical exam was unremarkable except for tenderness over the pacemaker site. No murmurs were appreciated. Laboratory evaluation showed the following values: white blood cells,7800 /μL; hemoglobin, 13.4 g/dL; and platelets, 151 × 109/L. Two sets of blood cultures revealed no growth at 5 days. Transthoracic echocardiography (TTE) showed 1.2 cm mobile mass attached to the ICD lead at the base of the posterior leaflet of the tricuspid valve suggestive of vegetation (Fig. 1A). At day 2 after admission, the patient was taken to the operating room where the entire pacing system was removed. The patient was found to have 25mLof purulent fluid which was. The acid-fast stain was positive (Fig. 1B, left panel), while the gram stain from the intraoperative culture showed beaded gram-positive bacilli (Fig. 1B, right panel). TEE showed hypoechoic mobile vegetation on the tricuspid valve measuring 0.87 cm without evidence of tricuspid regurgitation (Fig. 1C).
Fig. 1

A case of native valve endocarditis and pacemaker infection with Mycobacterium fortuitum.

(A) Two-dimensional transthoracic echocardiography showing 1.2 cm mobile mass attached to the pacemaker lead at the base of the posterior leaflet of the tricuspid valve. (B) Gram stain from OR cultures showing beady gram-positive bacilli (right panel); acid-fast stain showing positive Mycobacterium (bright pink, left panel). (C) Two-dimensional transesophageal echocardiography showing 0.872 mm vegetation on the tricuspid valve.

A case of native valve endocarditis and pacemaker infection with Mycobacterium fortuitum. (A) Two-dimensional transthoracic echocardiography showing 1.2 cm mobile mass attached to the pacemaker lead at the base of the posterior leaflet of the tricuspid valve. (B) Gram stain from OR cultures showing beady gram-positive bacilli (right panel); acid-fast stain showing positive Mycobacterium (bright pink, left panel). (C) Two-dimensional transesophageal echocardiography showing 0.872 mm vegetation on the tricuspid valve. At day 5 after admission, the patient was treated empirically with azithromycin (250 mg per mouth daily), imipenem/cilastatin (1 g intravenously every 8 h), amikacin (17 mg/kg intravenously three times per week) and tigecycline (250 g intravenously every 24 h). The surgical specimen was sent to Mayo Clinic (Rochester, Minnesota) for further testing and M. fortuitum was identified by DNA probe analysis. The patient developed significant nausea 5 days after tigecycline was started and this was switched to levofloxacin (750 mg per mouth daily). Drug resistance testing by broth microdilution of the M. fortuitum isolate indicated that this isolate was resistant to macrolides and tobramycin, intermediate to cefoxitin (MIC 32 μg/mL −1), and susceptible to amikacin (MIC <1 μg/mL− 1), imipenem (MIC 4 μg/mL− 1), tigecycline (MIC 0.12 μg/mL− 1), ciprofloxacin (MIC < 0.12 μg/mL− 1), moxifloxacin (MIC < 0.25 μg/mL− 1), linezolid (MIC 4 μg/mL− 1), doxycycline (MIC < 0.25 μg/mL− 1), and trimethoprim/sulfamethoxazole (MIC 2/38 μg/mL− 1). At days16 after admission, the patient was discharged. The patient completed the multidrug treatment regimen of azithromycin, levofloxacin, imipenem/cilastatin, and amikacin for 6 weeks and was subsequently switched to oral trimethoprim/sulfamethoxazole (800−160 mg twice daily) plus doxycycline (100 mg twice daily) for a further 12 weeks. At weeks 18 after the start of therapy, the patient discovered she was pregnant, and her oral antibiotics were stopped. The patient completed 4.5months of treatment in total. A follow up transeophageal echocardiography at 20 weeks after discharge showed no vegetation.

Discussion

Cardiovascular infection with M. fortuitum is rarely encountered in clinical practice. However, M. fortuitum infection of a pacemaker system with associated endocarditis has been described previously [1]. We searched the available literature using PubMed with no starting date restrictions through September 31, 2020 and identified only 12 previously reported cases of cardiovascular implantable electronic device (CIED) infections caused by M. fortuitum including our patient species (Table 1). We observed that 4 (33.3 %) of the 12 patients with M. fortuitum infection had associated mycobacteremia [3,[9], [10], [11]].
Table 1

Pacemaker infections due to M. fortuitum.

Year(Ref)Age/SexTime from implantPresenting signs and symptomsBacteremiaValve or lead vegetationTime to diagnosisMethod of diagnosisPacemaker removalAntibiotics treatmentDuration of treatmentOutcome
1998 [2]74/F13 daysFever, pain and purulent dischargeNoNR2 daysCulture of pusYesOfloxacin + gentamycin1 monthCured
2005 [3]62/F6 monthsFever, erythemaYesYes (atrial lead)1 monthCulture of aspirateYesCiprofloxacin/ clarithromycin6 monthsCured
2005 [8]72/F2 weeksSubcutaneous nodules and chronic drainageNoNo1 weekAbscess cultureYesAmikacin/ ciprofloxacin6 monthsCured
2006 [9]80/M18 daysNRYesNoNRNRNoCiprofloxacin/ clarithromycin6 weeksCured
2006 [1]78/F6 monthsSwelling and discomfort over the pacemaker pocket.YesYes (right atrial lead)2 weeks16S ribosomal RNAYesLinezolid + levofloxacin + clarithromycin6 monthsCured
2007 [4]84/F2 monthsFever, pain, and erythemaNoNo7 days16S rRNA PCR and culture of aspirateYeslevofloxacin3 monthsCured
2009 [10]15/F7 weeksGreenish discharge and feverYesYes (endocardial and epicardial leads)3 daysLead cultureYesCiprofloxacin/ clarithromycin6 monthsCured
2010 [12]78/MNRNot reportedNRYes (non-specific pacemaker infection)NRNRNRCiprofloxacin/ Clarithromycin26 weeksCured
2011 [8]61/M17 monthsCutaneous infection overlying the generatorNoNo1 yearLead cultureYesLevofloxacin + amikacinNRCured
2012 [11]43/M4 yearsFever, night sweats, and weight lossYesYes (right ventricular lead)157 daysLead cultureYesClarithromycin/ ciprofloxacin/ amikacin22 weeksDied
2012 [5]56/M4 monthsPain and swelling at the BiV ICD pocket siteNoYes (right atrial and ventricular leads)10 daysOR cultureYesMeropenem + linezolid + doxycyclineCourse complicated by right middle cerebral artery (MCA) infarct and withdrawal of care with subsequent death
202027/F1 monthFever, purulent dischargeNoYes (tricuspid valve and ICD lead)1 monthOR cultureYesAzithromycin + Levofloxacin + imipenem then TMX/SMX + doxycycline4.5 monthsCured
Pacemaker infections due to M. fortuitum. This finding indicates that the infection had spread beyond the device pocket to the intravascular component of the CIED system, suggesting endovascular infection. In the 4 patients for which positive blood culture results were reported, 3 (31 %) had lead vegetation seen on echocardiographic images [3,9,11]. None of these three patients had evidence of valvular vegetation. The fourth patient had negative echocardiographic images, but she fulfilled pathologic criteria for infective endocarditis based on the isolation of the organism in an operative culture [10,13]. This patient was the only one with valvular endocarditis among all the reports in our review. We did not find any cases that described valvular vegetations on transthoracic echocardiogram (TTE) nor transesophageal echocardiogram (TEE). We believe that our case is the first case that described pacemaker and valvular and lead vegetations seen on echocardiogram images. The initial transthoracic echocardiogram (TTE) showed lead but no valvular vegetations. The transesophageal echocardiogram (TEE) confirmed a tricuspid valve vegetation. TTE has variable sensitivity for the detection of vegetations (<50 % to >90 % positive), indicating that a negative study does not exclude infective endocarditis (IE). TEE is also more sensitive than conventional TTE. In one report of 96 patients with IE [14], the sensitivity of TEE was 100 %, compared with 63 % for TTE, and the specificity values were identical (98 %). The first documented case of pacemaker infection associated with M. fortuitum alone was reported in 2005, it was successfully treated with ciprofloxacin/clarithromycin for 6 months and removal of the entire pacing system [3].This patient had associated mycobacteremia and evidence of lead but not valvular vegetation. All other reported cases were cured with a combination of antimicrobials, except for in the case reported by Giannella et al., in which the patient was treated with quinolone monotherapy because the bacteria was resistant to the remaining agents [4], and in a report by Hu et al., in which the patients course was complicated by a stroke, withdrawal of care, and subsequent death [5]. All reported cases involved the removal of the pacemaker system, except for the case by Pastor et al., in which the patient was treated with ciprofloxacin and clarithromycin for 6 weeks total [9]. Other cases of native valve endocarditis (in patients who did not have any cardiac devices) caused by M. fortuitum have also been reported (Table 2). The first reported case of native valve endocarditis due to M. fortuitum with visible vegetations on echocardiography was reported in 2000 [7]. Spell et al. described a 47-year-old male with newly diagnosed HIV whose blood cultures grew M. fortuitum. Initial transthoracic echocardiography showed no evidence of vegetations, but the repeated transthoracic echocardiography at 3 weeks later displayed peduncular vegetations on the left coronary, noncoronary, and right coronary cusps of the aortic valve. The patient was treated with amikacin, cefoxitin, and ciprofloxacin for a total of 6 weeks then switched to oral ciprofloxacin and trimethoprim-sulfamethoxazole. The patient died 12 weeks after his initial clinical presentation.
Table 2

Native valve endocarditis due to M. fortuitum.

Year (Ref)Age/sexPresenting signs and symptomsBacteremiaValve affectedTime to diagnosisMethod of diagnosisSurgical therapyAntibiotics therapyDuration of treatmentOutcome
1992 [6]54/FFever, headache, productive cough, shortness of breath, feverYesMitral + aortic2 weeksBlood culturesNoAmoxycillin, TMP/SMX, ciprofloxacin, clofazimine, cefoxitin, amikacin6 weeksDied
1999 [15]20/FNRNRMitralNRNRNoAmikacin, azithromycin, rifampinNRDied
2000 [7]47/MDysphagia, odynophagia, fever, and chillsYesAortic8 daysBlood culturesNo, patient preferred medical managementAmikacin, cefoxitin,ciprofloxacin,6 weeksPatient died 12 weeks after his initial clinical presentation
2015 [17]64/FPulmonary edema and multifocal pneumoniaYesPulmonicNRPCR of a tracheal aspirateNoAmikacin, imipenem, and clarithromycin16 daysPatient decided to stop antibiotic therapy and entered hospice
2006 [16]50/MNRNRMitral + aorticNRNRAVR + MVRClarithromycin, imipenem, moxifloxacin, amikacinNRDied
2012 [18]49/FFever, malaise nauseaYesAortic + tricuspid15 daysBlood culturesNoLinezolid and ciprofloxacin, and oral TMP/SMX6−12 monthsNot reported
2013 [19]12/FFever, fatigueYesTricuspidNRGenoType Mycobacterium CM assayNoAmikacin, ciprofloxacin, and imipenem6 weeksAlive at 12months after diagnosis
2/FFever, fatigueYesTricuspidNRGenoType Mycobacterium CM assayNoAmikacin, ciprofloxacin, and imipenem6 weeks
0.5/FFever, fatigueYesTricuspidNRGenoType Mycobacterium CM assayVSD patch removalAmikacin, ciprofloxacin, and imipenem6 weeks
Current27/FFeverNoTricuspid1 monthOR culture, DNA Gene probeNoAzithromycin + Levofloxacin + imipenem then TMX/SMX + doxycycline4.5 monthsCured
Native valve endocarditis due to M. fortuitum. Owing to the rarity of non-tuberculous mycobacteria-related cardiac device-associated infective endocarditis, there are no clear management guidelines for the type and duration of therapy. Based on prior reports, a combination of two or three drugs for 6−12 months appears necessary. The choice of antibiotics depends on the results of susceptibility testing. M. fortuitum isolates are usually susceptible to multiple oral antimicrobial agents, including newer macrolides, quinolones, doxycycline, minocycline, and sulfonamides. Removal of the infected pacemaker device is of paramount importance given the high replapse rate despite prolonged antimicrobial therapy. In summary, we describe a rare case of pacemaker infection and native valve endocarditis with M. fortuitum, which highlights this mycobacterium as an important possible cause of cardiovascular infections.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest

None.
  19 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

Review 2.  Pacemaker infection due to Mycobacterium fortuitum.

Authors:  Sunita Sharma; Imad M Tleyjeh; Raul E Espinosa; Brian A Costello; Larry M Baddour
Journal:  Scand J Infect Dis       Date:  2005

3.  Pacemaker implant site infection caused by atypical mycobacteria.

Authors:  S Verghese; A Mullaseri; P Padmaja; A C Subhadra; K M Cherian
Journal:  Indian Heart J       Date:  1998 Mar-Apr

4.  Improved diagnostic value of echocardiography in patients with infective endocarditis by transoesophageal approach. A prospective study.

Authors:  R Erbel; S Rohmann; M Drexler; S Mohr-Kahaly; C D Gerharz; S Iversen; H Oelert; J Meyer
Journal:  Eur Heart J       Date:  1988-01       Impact factor: 29.983

5.  Native double-valve endocarditis by Mycobacterium fortuitum following percutaneous coronary intervention.

Authors:  Sathiakar Paul Collison; Naresh Trehan
Journal:  J Heart Valve Dis       Date:  2006-11

6.  Fortuitous vasculitis.

Authors:  Hema Sharma; Ashvini Keshavan; Mark Alan Little; Jennifer Cross; Marc C Lipman; Sabrina Talukdar; Susan Hopkins
Journal:  Ren Fail       Date:  2012-01-17       Impact factor: 2.606

Review 7.  Myocardial abscess and bacteremia complicating Mycobacterium fortuitum pacemaker infection: case report and review of the literature.

Authors:  Hussam Al Soub; Mona Al Maslamani; Jameela Al Khuwaiter; Yasser El Deeb; Mohammed Abu Khattab
Journal:  Pediatr Infect Dis J       Date:  2009-11       Impact factor: 2.129

8.  Native Pulmonic Valve Endocarditis due to Mycobacterium fortuitum: A Case Report and Literature Review.

Authors:  Aaron M Mulhall; Renee S Hebbeler-Clark
Journal:  Case Rep Infect Dis       Date:  2015-06-08

9.  A mysterious gram-positive rods.

Authors:  Javzandulam Natsag; Zaw Min; Yasir Hamad; Bassel Alkhalil; Atiq Rahman; Richard Williams
Journal:  Case Rep Infect Dis       Date:  2012-08-22

10.  Mycobacterium fortuitum endocarditis associated with cardiac surgery, Serbia.

Authors:  Dragana Vuković; Vojislav Parezanović; Branislava Savić; Ivana Dakić; Suzana Laban-Nestorović; Slobodan Ilić; Ivana Ćirković; Srdjan Stepanović
Journal:  Emerg Infect Dis       Date:  2013-03       Impact factor: 6.883

View more
  1 in total

1.  Cardiovascular device infections due to rapidly growing Mycobacteria: A review of cases at a tertiary care hospital.

Authors:  Isin Yagmur Comba; Supavit Chesdachai; Hussam Tabaja; Maryam Mahmood; Sharon Deml; Nancy L Wengenack; John W Wilson
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-01-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.